Clinical trial
A Non-interventional Study of Selinexor (Nexpovio®) in Combination With Bortezomib and Dexamethasone (SVd) in Patients With Relapsed or Refractory Multiple Myeloma (R/RMM)
NCT05954780 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional Study of Selinexor (Nexpovio®) in Combination With Bortezomib and Dexamethasone (SVd) in Patients With Relapsed or Refractory Multiple Myeloma (R/RMM)
- Lead sponsor
- iOMEDICO AG
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- June 28, 2023
- Completion date
- October 30, 2026
- Enrollment
- 75 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.